Treatment-free Remission Accomplished With Dasatinib in Patients With CML
The purpose of this study is to find out how to increase the potential for achieving an
"operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which
a person does not require further treatment, although there may be some remaining cancer
cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of
care setting for chronic myeloid leukemia. Within this clinical trial, patients will
discontinue their TK inhibitor prematurely. If any signs of progression are identified,
dasatinib will be introduced.
This research is being done because dasatinib has been shown to achieve a greater response
in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately
300 times more potent than imatinib, and it is possible that a greater response can be
achieved by dasatinib than by imatinib.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society